Reversal of human neutrophil survival by leukotriene B(4) receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitors.
about
Activation of adherent vascular neutrophils in the lung during acute endotoxemiaNeutrophil plasticity enables the development of pathological microenvironments: implications for cystic fibrosis airway diseaseA turn on and a turn off: BLT1 and BLT2 mechanisms in the lungIr-LBP, an ixodes ricinus tick salivary LTB4-binding lipocalin, interferes with host neutrophil function.Environmental and genetic risk factors and gene-environment interactions in the pathogenesis of chronic obstructive lung diseaseSmoking status and anti-inflammatory macrophages in bronchoalveolar lavage and induced sputum in COPD.Dexamethasone effects in the Strongyloides venezuelensis infection in a murine model.Novel therapies for the treatment of inflammatory airway disease.Role of leukotrienes in the regulation of human granulocyte behaviour: dissociation between agonist-induced activation and retardation of apoptosis.Peculiarities of cell death mechanisms in neutrophils.Induced sputum cell profiles in lung transplant recipients with or without chronic rejection: correlation with lung functionInhibition of leukotriene B4-induced CD11B/CD18 (Mac-1) expression by BIIL 284, a new long acting LTB4 receptor antagonist, in patients with rheumatoid arthritisRole of neutrophils in mucus hypersecretion in COPD and implications for therapy.Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease.Eicosanoids and respiratory viral infection: coordinators of inflammation and potential therapeutic targets.Handle with care: targeting neutrophils in chronic obstructive pulmonary disease and severe asthma?The effects of n-3 polyunsaturated fatty acid-rich total parenteral nutrition on neutrophil apoptosis in a rat endotoxemia.Aspects on pathophysiological mechanisms in COPD.Leukotriene pathway genetics and pharmacogenetics in allergy.Modulation of Neutrophil Apoptosis and the Resolution of Inflammation through β2 Integrins.Targeting 5-lipoxygenase-activating protein in asthma and chronic obstructive pulmonary disease.Neutrophilic Inflammation in Asthma and Association with Disease Severity.MicroRNA Expression in Cystic Fibrosis Airway Epithelium.Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals.Cysteinyl leukotriene E4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D2 and epithelial cytokines.Pulmonary function changes and immunomodulation of cytokine expression by zafirlukast after sensitization and allergen challenge in brown Norway rats.Increased leukotrienes in exhaled breath condensate in childhood asthma.Biological effects of montelukast, a cysteinyl-leukotriene receptor-antagonist, on T lymphocytes.Breath condensate levels of 8-isoprostane and leukotriene B4 after ozone inhalation are greater in sensitive versus nonsensitive subjects.PI3K and MAPKs regulate neutrophil migration toward the airways in heaves.Overview of novel therapeutic targets for asthma and chronic obstructive pulmonary disease.
P2860
Q24802326-5F297F05-A48D-4514-8435-0C0709DE21E8Q28071357-53BD2D6A-AC57-49EE-B067-D2358724AD20Q28238376-5053F15F-0BDA-4F48-B8F9-7B38CDCDAEA7Q33394578-6B14EBC2-88FD-4771-A5EB-C469777AF5BEQ33994809-1CA1CDE0-1C65-43EE-A530-E5DD6871785DQ34774344-A4886D00-5DD5-49C3-A74D-7597C5D2696CQ35031915-18201ABC-1A65-4D2E-AB96-665D080CA448Q35040779-7A337F4B-4934-41A1-9DE9-0599303B407CQ35045349-F4D96355-D727-4BAD-8F71-8D3DB3D48AE0Q35227431-FEDC93E9-9E27-4671-9DA5-AA41DA3F2922Q35534596-2D98B025-2841-4B13-9CE7-F2F702845A76Q35553767-394FDFA2-D54B-45A3-BBD8-02A9B7925E94Q35818337-391D85D3-3B5B-43FC-9533-EF92B08BC699Q35841604-60C23412-2BD6-4D29-BCA2-1993DBEA7BE6Q35994233-0E9EE421-BD39-4643-AC24-733A0FC7889DQ36376519-D0F3BC4E-7A7F-4DCF-B784-6FCE50C908B8Q36670824-B91F16BF-16AE-42B4-80A9-4122329E9324Q36909567-B241216A-1168-4B2B-9D6D-B9418AFCAC96Q37470762-87E3710C-EF46-4F1F-A7FF-4D2FB3469869Q38091028-CB6E381F-36E8-4E9C-B561-41621058B2F1Q38248535-5FCE70F7-71FD-49E4-9744-35F3805A6ECCQ38645834-8C99DAD6-8F04-4E72-9AB0-39F7ED7605C2Q39869793-77F6237B-1496-4D6B-9A82-C061DA1C0586Q40874080-3B2FAE84-1CD0-4D22-AAFF-5DC2D9AA966EQ42118581-D2B790E5-DA91-4BA1-8E1E-213F0699C2F1Q44016413-988C46A0-1ACD-490E-9A7A-7B01C9789F0AQ44198490-0B5D0AE0-E479-4CE2-ABA9-6AEBFF07CA51Q45233080-AC654711-E086-4A8E-B936-C339379C9E85Q45953853-F066BCD0-C37D-485F-9706-6DB7FF5BCA11Q46715284-06B2196F-47E5-4769-9888-616DEEFFED90Q47772639-3A8239A1-5107-4FE2-8EA0-7643E110E5E5
P2860
Reversal of human neutrophil survival by leukotriene B(4) receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitors.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Reversal of human neutrophil survival by leukotriene B
@nl
Reversal of human neutrophil s ...... activating protein inhibitors.
@en
type
label
Reversal of human neutrophil survival by leukotriene B
@nl
Reversal of human neutrophil s ...... activating protein inhibitors.
@en
prefLabel
Reversal of human neutrophil survival by leukotriene B
@nl
Reversal of human neutrophil s ...... activating protein inhibitors.
@en
P2093
P2860
P1476
Reversal of human neutrophil s ...... activating protein inhibitors.
@en
P2093
L Meng-Choong
P Reynolds
S Kilfeather
P2860
P304
P356
10.1164/AJRCCM.160.6.9903136
P407
P577
1999-12-01T00:00:00Z